Nitya Ray - Actinium Pharmaceuticals Insider

ATNM -- USA Stock  

USD 0.74  0.0083  1.14%

  President
Dr. Nitya G. Ray Ph.D. is Executive Vice President, Head Product Development, Manufacturing and Supply Chain of the company. Dr. Ray joins the Company from CytoDyn, Inc. where he was Sr. Vice President of Manufacturing and CMC Team Leader. At CytoDyn Dr. Ray developed robust and cost effective manufacturing processes for an antibody therapeutic drug candidate, currently in two Phase 3 clinical studies intended to treat and prevent HIV infection. Dr. Ray led a successful regulatory meetings with the FDA while simultaneously developing strategies for process development, scaleup, validation, commercial manufacturing, and supply chain to support potential commercialization of the CytoDyn HIV therapeutic drug candidate. Prior to CytoDyn, Dr. Ray spent 15 years at Progenics Pharmaceuticals, Inc. a radiopharmaceutical therapeutic and diagnostic company, most recently as Senior Vice President, Manufacturing. At Progenics, Dr. Ray led the development of scalable manufacturing processes and achieved orderofmagnitude cost reduction through improved productivity and scale. In addition, Dr. Ray built process and product development teams for Progenics small molecule, biologics, and radiopharmaceuticals that developed innovative processes for various phases of clinical development and commercial manufacturing. Dr. Ray supported inhouse cGMP biologics manufacturing for Phase 13 clinical development and managed relationships with Contract Development and manufacturing Organizations on a global basis. Dr. Ray also worked at HoffmanLa Roche with a focus on biopharmaceuticals and Verax Corporationrationration in roles of increasing responsibility
Age: 62  President Since 2017      
646-767-3870  http://www.actiniumpharma.com
Ray has a Ph.D. in Biochemical Engineering and an M.S. in Chemical and Biochemical Engineering from Rutgers University and a B.S. in Chemical Engineering from Jadavpur University.

Nitya Ray Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (81.44) % which means that it has lost $81.44 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (173.14) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Found 11 records

PRESIDENT Since

Alyssa WyantEdge Therapeutics
2017
Kevin LaliberteDova Pharmaceuticals
2017
Bradford MiddlekauffEdge Therapeutics
2015
David MozleyEndocyte
2015
David JohnsonDynavax Technologies Corporatio
2014
Michael OstrachDynavax Technologies Corporatio
2016
Robert JanssenDynavax Technologies Corporatio
2018
Erik CheliusEndocyte
2018
Michael BrinkleyEndocyte
2013
Theodore AshburnDicerna Pharmaceuticals
2014
Katherine ParkerEndocyte
2015

Entity Summary

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York. Actinium Pharmaceuticals operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 25 people.Actinium Pharmaceuticals (ATNM) is traded on BATS Exchange in USA. It is located in NEW YORK U.S.A and employs 25 people. Actinium Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Actinium Pharmaceuticals Leadership Team

Nitya Ray, Executive Vice President Head - Product Development, Manufacturing and Supply Chain
Dale Ludwig, Chief Scientific Officer
Sergio Traversa, Interim CFO, Independent Director
Dragan Cicic, COO, Chief Medical Officer
Steve OLoughlin, Principal Financial and Accounting Officer
Vijay Reddy, Vice President Clinical Development
Kaushik Dave, President CEO, Director
Ajit Shetty, Independent Director
Richard Steinhart, Director
Anil Kapur, Chief Commercial Officer
David Nicholson, Independent Director
Jehan Rowlands, Vice President and Head - Regulatory Affairs
C Nicholson, Independent Director
Robert Daly, Vice President Head - Clinical Operations
Mark Berger, Chief Medical Officer
Jeffrey Chell, Independent Director
Steven Price, Vice President - Clinical and Commercial Strategy
Sandesh Seth, Chairman of the Board

Stock Performance Indicators

Did you try this?

Run Price Transformation Now

   

Price Transformation

Use Price Transformation models to analyze depth of different equity instruments across global markets
All  Next Launch Price Transformation

Actinium Pharmaceuticals Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Actinium Pharmaceuticals and China Cord Blood. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Pair Correlation module to compare performance and examine historical correlation between any two equity instruments.
Search macroaxis.com